Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coherus Shelves Eylea Biosimilar And Rules Out Early-Stage Biosimilar Development

Biosimilars Leader Coherus Marks New Era With Immuno-Oncology Play

Executive Summary

Coherus BioSciences, a leader and innovator in the nascent US biosimilars space, has announced plans to ditch a key biosimilar opportunity and limit overall investment, in order to direct resources to immuno-oncology.

You may also be interested in...

Is The Bloom Off The Rose For Big Pharma And Biosimilars?

After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.

Coherus Makes U-Turn On Eylea Biosimilar With Klinge BioPharma Deal

Buoyed by the recent launch and leverage of its biosimilar ranibizumab biosimilar, Coherus BioSciences has brokered a deal with Klinge BioPharma/Formycon for the commercialization rights to the firms’ Eylea (aflibercept) biosimilar candidate

Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar

Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts